Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Highly specialised technologies guidance
Reference number: HST20
Published: 05 May 2022

History

Final evaluation determination

Final evaluation determination
Final evaluation determination document (PDF 295 KB)

Published:

01 April 2022
Public committee slides (PDF 1.08 MB)

Published:

01 April 2022
Committee papers (PDF 1.47 MB)

Published:

01 April 2022

Evaluation consultation: 1

Evaluation consultation: 1
Evaluation consultation document (PDF 282 KB)

Published:

02 December 2021
Committee papers (PDF 4.86 MB)

Published:

02 December 2021
Public committee slides November 2021 (PDF 1.41 MB)

Published:

02 December 2021
Evaluation consultation document (Online commenting)

Invitation to participate

Equality impact assessment (Scoping) (PDF 129 KB)

Published:

15 June 2021
Final scope (PDF 200 KB)

Published:

15 June 2021
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 293 KB)

Published:

15 June 2021
Final stakeholder list (PDF 186 KB)

Published:

15 June 2021

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft matrix post referral (PDF 184 KB)

Published:

15 June 2021
Draft scope post referral (PDF 232 KB)

Published:

15 June 2021